Reduction of CA125 Levels During Neoadjuvant Chemotherapy Can Predict Cytoreduction to No Visible Residual Disease in Patients with Advanced Epithelial Ovarian Cancer, Primary Carcinoma of Fallopian tube and Peritoneal Carcinoma

Lignende værker

• The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma
  af: Vasudev, Naveen S., et al.
  Udgivet: (2010)
• Incidence of Ovarian, Peritoneal, and Fallopian Tube Carcinomas in the United States, 1995–2004
  af: Goodman, Marc T., et al.
  Udgivet: (2009)
• Optimal Primary Management of Bulky Stage IIIC Ovarian, Fallopian Tube and Peritoneal Carcinoma: Are the Only Options Complete Gross Resection at Primary Debulking Surgery or Neoadjuvant Chemotherapy?
  af: Sioulas, Vasileios D., et al.
  Udgivet: (2017)
• A Multicenter Prospective Trial Evaluating the Ability of Preoperative Computed Tomography Scan and Serum CA-125 to Predict Suboptimal Cytoreduction at Primary Debulking Surgery for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer
  af: Suidan, Rudy S., et al.
  Udgivet: (2014)
• Benign Ovarian Cysts with Raised CA-125 Levels: Do We Need to Evaluate the Fallopian Tubes?
  af: Sharma, Devesh, et al.
  Udgivet: (2020)